TOP HEADLINES

Featured Story

Sarepta's boardroom intrigue clouds a promising drug's future

After Sarepta Therapeutics' former head scientist blamed his swift ouster on "serious disagreements" with CEO Chris Garabedian, the company has moved to limit its chief executive's power, according to a report, especially when it comes to meetings with the FDA over the biotech's much-scrutinized lead drug.

UPDATED: Amgen axing up to 2,900 staffers, shuttering sites in major restructuring

Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.

Quark's RNAi treatment misses the mark in a Phase II kidney trial

Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with Novartis worth up to $680 million.

Merck Serono steps into IO spotlight with PhII cancer study

Looking to share some of the spotlight focused on the immuno-oncology arena, Merck Serono says it has launched a mid-stage study of MSB0010718C, an anti-PD-L1 antibody.

Resurgent Merck to accelerate R&D spending in H2, hunt new drug deals

With investors focused almost exclusively on earnings and R&D programs today, Merck quietly managed to slip in news of a setback in its quarterly report, noting that the FDA has rejected its marketing application for the fertility treatment corifollitropin alfa.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Nobel Biocare has confirmed it is in early discussions with potential buyers, after a Bloomberg article reported a rumored sale. The report said the company has hired Goldman Sachs to broker a transaction.

FierceDrugDelivery

Mannkind endured a grueling 10-year battle for FDA approval of its inhaled insulin drug/device combination product, Afrezza. Now the dillema is how to sell it. The company needs to find a marketing partner fast.